Corporate

Astellas promotes Moyra Knight to comms, corporate citizenship role

Astellas promotes Moyra Knight to comms, corporate citizenship role

By

She will also continue to serve as president of the Astellas U.S.A. Foundation.

W2O's Twist hires new president

W2O's Twist hires new president

By

Former Edelman executive Mary Corcoran replaces Annalise Coady, who becomes president of W2O EMEA.

Five things for pharma marketers to know: Wednesday, August 2, 2017

Five things for pharma marketers to know: Wednesday, August 2, 2017

By

Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

By

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Five things for pharma marketers to know: Thursday, July 27, 2017

Five things for pharma marketers to know: Thursday, July 27, 2017

By

Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug

Astellas promotes two sales veterans to new roles

Astellas promotes two sales veterans to new roles

By

David Musselman and Lynn Gerber are now leading sales for the company's primary care and specialty products.

Five things for pharma marketers to know: Tuesday, July 25, 2017

Five things for pharma marketers to know: Tuesday, July 25, 2017

By

Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review

Five things for pharma marketers to know: Tuesday, July 18, 2017

Five things for pharma marketers to know: Tuesday, July 18, 2017

By

Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy

Five things for pharma marketers to know: Thursday, July 13, 2017

Five things for pharma marketers to know: Thursday, July 13, 2017

By

AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge

Questions for 5 of the healthcare agency world's top execs

Questions for 5 of the healthcare agency world's top execs

By

The CEOs of the industry's largest holding companies discuss how they're reasserting their businesses.

MM&M's 2017 healthcare agency solar system

MM&M's 2017 healthcare agency solar system

Discover how M&A activity in 2016 and 2017 has reshaped North American healthcare agencies and the holding companies that own them.

Five things for pharma marketers to know: Thursday, June 29, 2017

Five things for pharma marketers to know: Thursday, June 29, 2017

By

Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition

Johnson & Johnson CMO: Innovation needs to sit outside the bottle

Johnson & Johnson CMO: Innovation needs to sit outside the bottle

By

Alison Lewis, the global chief marketing officer of Johnson & Johnson consumer division, has little appetite for new flavours and variants but instead wants to rethink innovation as a means to solve consumer problems.

Pfizer celebrates the faces behind its vaccines with documentary

Pfizer celebrates the faces behind its vaccines with documentary

By

The video is part of Pfizer's ongoing corporate ad campaign Before it Became a Medicine.

Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

By

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Advocacy groups add a shade of resistance to Pride celebrations

Advocacy groups add a shade of resistance to Pride celebrations

By

The tone has changed dramatically since last year for LGBT rights groups, which are now as focused on opposing the Trump administration's policies as celebrating progress and community.

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

By By

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

Gilead Sciences | 2017

By

Hepatitis C is so 2015 — at least, that's what Gilead Sciences CEO John Milligan is saying following his first year at the helm.

Pfizer | 2017

By

Is Pfizer finally in a position to close the Lipitor chapter, the one titled "how to bounce back from monumental loss"? All signs indicate yes.

Johnson & Johnson | 2017

By

After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.

Merck | 2017

By

The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.

Amgen | 2017

By

Biotech major Amgen is making good on a lofty promise to generate $1.5 billion in savings by 2018.

Teva Pharmaceutical Industries | 2017

By

The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan.

AbbVie | 2017

By

Any conversation about AbbVie has to begin with Humira, the best-selling drug in the world and the drugmaker's most important product.

Sanofi | 2017

By

Sanofi has been browsing in the acquisition aisle for some time now, even wheeling a few companies to the register only to leave empty-handed.

Roche | 2017

By

The FDA made patients, providers, and investors very happy when it approved Roche's Ocrevus in March.

Novartis | 2017

By

Following one of the most anticipated exclusivity losses of the decade, sales of Novartis cancer drug Gleevec slipped 28% in 2016 to $3.3 billion.

Eli Lilly | 2017

By

Eli Lilly has faced a rough patch. Last November, the company took a $150 million charge over its failed high-profile Alzheimer's disease drug solanezumab.

AstraZeneca | 2017

By

AstraZeneca brought its internal overhaul A game in 2016, leaving investors humming the tune of a much-needed turning point.

Five things for pharma marketers to know: Friday, May 26, 2017

Five things for pharma marketers to know: Friday, May 26, 2017

By

FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes